146 related articles for article (PubMed ID: 16290935)
41. Synthesis of substituted 5[H]phenanthridin-6-ones as potent poly(ADP-ribose)polymerase-1 (PARP1) inhibitors.
Li JH; Serdyuk L; Ferraris DV; Xiao G; Tays KL; Kletzly PW; Li W; Lautar S; Zhang J; Kalish VJ
Bioorg Med Chem Lett; 2001 Jul; 11(13):1687-90. PubMed ID: 11425538
[TBL] [Abstract][Full Text] [Related]
42. Structure-based design of new poly (ADP-ribose) polymerase (PARP-1) inhibitors.
Chadha N; Jaggi AS; Silakari O
Mol Divers; 2017 Aug; 21(3):655-660. PubMed ID: 28653128
[TBL] [Abstract][Full Text] [Related]
43. A versatile strategy for the design and synthesis of novel ADP conjugates and their evaluation as potential poly(ADP-ribose) polymerase 1 inhibitors.
Sherstyuk YV; Zakharenko AL; Kutuzov MM; Chalova PV; Sukhanova MV; Lavrik OI; Silnikov VN; Abramova TV
Mol Divers; 2017 Feb; 21(1):101-113. PubMed ID: 27677737
[TBL] [Abstract][Full Text] [Related]
44. Inhibitor-induced structural change of the active site of human poly(ADP-ribose) polymerase.
Kinoshita T; Nakanishi I; Warizaya M; Iwashita A; Kido Y; Hattori K; Fujii T
FEBS Lett; 2004 Jan; 556(1-3):43-6. PubMed ID: 14706823
[TBL] [Abstract][Full Text] [Related]
45. On the way to selective PARP-2 inhibitors. Design, synthesis, and preliminary evaluation of a series of isoquinolinone derivatives.
Pellicciari R; Camaioni E; Costantino G; Formentini L; Sabbatini P; Venturoni F; Eren G; Bellocchi D; Chiarugi A; Moroni F
ChemMedChem; 2008 Jun; 3(6):914-23. PubMed ID: 18409175
[TBL] [Abstract][Full Text] [Related]
46. Rational design of conformationally restricted quinazolinone inhibitors of poly(ADP-ribose)polymerase.
Hattori K; Kido Y; Yamamoto H; Ishida J; Iwashita A; Mihara K
Bioorg Med Chem Lett; 2007 Oct; 17(20):5577-81. PubMed ID: 17804225
[TBL] [Abstract][Full Text] [Related]
47. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.
Calabrese CR; Batey MA; Thomas HD; Durkacz BW; Wang LZ; Kyle S; Skalitzky D; Li J; Zhang C; Boritzki T; Maegley K; Calvert AH; Hostomsky Z; Newell DR; Curtin NJ
Clin Cancer Res; 2003 Jul; 9(7):2711-8. PubMed ID: 12855651
[TBL] [Abstract][Full Text] [Related]
48. Identification of ring-fused pyrazolo pyridin-2-ones as novel poly(ADP-ribose)polymerase-1 inhibitors.
Moree WJ; Goldman P; Demaggio AJ; Christenson E; Herendeen D; Eksterowicz J; Kesicki EA; McElligott DL; Beaton G
Bioorg Med Chem Lett; 2008 Sep; 18(18):5126-9. PubMed ID: 18713665
[TBL] [Abstract][Full Text] [Related]
49. 3. Life or death decisions: the cast of poly(ADP-ribose)polymerase (PARP) as a therapeutic target for brain ischaemia.
Pellicciari R; Camaioni E; Costantino G
Prog Med Chem; 2004; 42():125-69. PubMed ID: 15003720
[No Abstract] [Full Text] [Related]
50. Synthesis of isoquinolinone-based tetracycles as poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors.
Rhee HK; Lim SY; Jung MJ; Kwon Y; Kim MH; Choo HY
Bioorg Med Chem; 2009 Nov; 17(21):7537-41. PubMed ID: 19800803
[TBL] [Abstract][Full Text] [Related]
51. Identification of low micromolar dual inhibitors for aldose reductase (ALR2) and poly (ADP-ribose) polymerase (PARP-1) using structure based design approach.
Chadha N; Silakari O
Bioorg Med Chem Lett; 2017 Jun; 27(11):2324-2330. PubMed ID: 28438542
[TBL] [Abstract][Full Text] [Related]
52. Strategies Employed for the Development of PARP Inhibitors.
Canan S; Maegley K; Curtin NJ
Methods Mol Biol; 2017; 1608():271-297. PubMed ID: 28695516
[TBL] [Abstract][Full Text] [Related]
53. Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP).
Griffin RJ; Srinivasan S; Bowman K; Calvert AH; Curtin NJ; Newell DR; Pemberton LC; Golding BT
J Med Chem; 1998 Dec; 41(26):5247-56. PubMed ID: 9857092
[TBL] [Abstract][Full Text] [Related]
54. Synthesis of isoquinolinone-based tricycles as novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
Chen J; Peng H; He J; Huan X; Miao Z; Yang C
Bioorg Med Chem Lett; 2014 Jun; 24(12):2669-73. PubMed ID: 24815508
[TBL] [Abstract][Full Text] [Related]
55. Identification and mechanism of action analysis of the new PARP-1 inhibitor 2″-hydroxygenkwanol A.
Dal Piaz F; Ferro P; Vassallo A; Vasaturo M; Forte G; Chini MG; Bifulco G; Tosco A; De Tommasi N
Biochim Biophys Acta; 2015 Sep; 1850(9):1806-14. PubMed ID: 25999161
[TBL] [Abstract][Full Text] [Related]
56. Discovery and SAR of novel, potent and selective hexahydrobenzonaphthyridinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).
Torrisi C; Bisbocci M; Ingenito R; Ontoria JM; Rowley M; Schultz-Fademrecht C; Toniatti C; Jones P
Bioorg Med Chem Lett; 2010 Jan; 20(2):448-52. PubMed ID: 20015648
[TBL] [Abstract][Full Text] [Related]
57. Ruthenium complexes as protein kinase inhibitors.
Zhang L; Carroll P; Meggers E
Org Lett; 2004 Feb; 6(4):521-3. PubMed ID: 14961613
[TBL] [Abstract][Full Text] [Related]
58. Pharmacological inhibition of PARP-1 reduces alpha-synuclein- and MPP+-induced cytotoxicity in Parkinson's disease in vitro models.
Outeiro TF; Grammatopoulos TN; Altmann S; Amore A; Standaert DG; Hyman BT; Kazantsev AG
Biochem Biophys Res Commun; 2007 Jun; 357(3):596-602. PubMed ID: 17449015
[TBL] [Abstract][Full Text] [Related]
59. Flavone as PARP-1 inhibitor: its effect on lipopolysaccharide induced gene-expression.
Geraets L; Moonen HJ; Brauers K; Gottschalk RW; Wouters EF; Bast A; Hageman GJ
Eur J Pharmacol; 2007 Nov; 573(1-3):241-8. PubMed ID: 17643414
[TBL] [Abstract][Full Text] [Related]
60. Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer.
Penning TD; Zhu GD; Gandhi VB; Gong J; Thomas S; Lubisch W; Grandel R; Wernet W; Park CH; Fry EH; Liu X; Shi Y; Klinghofer V; Johnson EF; Donawho CK; Frost DJ; Bontcheva-Diaz V; Bouska JJ; Olson AM; Marsh KC; Luo Y; Rosenberg SH; Giranda VL
Bioorg Med Chem; 2008 Jul; 16(14):6965-75. PubMed ID: 18541433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
